Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 07/06/2017 The fruit fly Drosophila is used as obesity model. The fat tissue has been visualised by way of GFP (green fluorescent protein) expression.

    A gene that regulates body heat and fat storage

    Researchers from Heidelberg have shown that the organismal balance between heat production and energy storage is regulated by a gene called THADA. In animal experiments, knocking out the THADA gene leads to excessive food intake, obesity and sensitivity to cold. As humans spread throughout the world and settled in different climate zones, THADA was exposed to high selection pressure due to evolutionary adaptation. This explains why human…

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-gene-that-regulates-body-heat-and-fat-storage
  • Article - 21/12/2016 Signatope GmbH’s founding team (from left to right) Prof. Dr. Hugo Hämmerle, Dr. Oliver Pötz, Dr. Hannes Planatscher, Dr. Octavian Schatz and Dr. Thomas Joos.

    For all types of tests: Signatope’s biomarker assays

    Signatope is a new biotech company that has been offering innovative biomarker assays for application in drug discovery since August 2016. The company’s assays can be used in all phases of drug development to detect potential adverse drug effects on the kidneys, liver and other organs in any species whatsoever using minute amounts of sample.

    https://www.gesundheitsindustrie-bw.de/en/article/news/for-all-types-of-tests-signatopes-biomarker-assays
  • Personalised medicine - 16/09/2021 Diagram illustrating pharmacogenomics. Individuals with different genetic makeups are shown as different coloured pictograms and have different combinations of efficacy and toxicity. A drawing of an hourglass is used to illustrate the influence of non-genetic factors.

    Pharmacogenomics enables individualised drug prescription

    Every person is unique, and their reaction to medications can be just as individual. For this reason, unexpected side effects occur time and again with common drugs, sometimes with life-threatening consequences. At the Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology (IKP) in Stuttgart, the influence of hereditary factors on these harmful reactions is being investigated in order to enable individualised therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/news/pharmacogenomics-enables-individualised-drug-prescription
  • Article - 12/09/2016 Photo of the building housing the Department of Internal Medicine in Tübingen.

    New target for the therapy of hepatocellular carcinoma discovered

    Hepatocellular carcinoma is the second most common cause of cancer deaths worldwide. If the tumour is at an advanced stage, doctors have few treatment options. Researchers led by Prof. Dr. Lars Zender from the University of Tübingen have now identified one of the cancer's Achilles' heels, namely, the interaction between C-MYC and AURKA proteins, which can be destabilised with a drug, thus killing cancer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-target-for-the-therapy-of-hepatocellular-carcinoma-discovered
  • Article - 25/01/2010 10570_de.jpg

    Treatment and Research Centre of Rare Diseases established in Tübingen

    On 22nd January 2010, the first German Treatment and Research Centre of Rare Diseases (ZSE) was officially opened in Tübingen. Interdisciplinary teams will from now on be developing new therapies under one roof for around three to four million patients suffering from rare diseases in Germany. The centre in Tübingen will offer optimal patient treatment, coordinate the cooperation between international specialists, and provide competent advice and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/treatment-and-research-centre-of-rare-diseases-established-in-tuebingen
  • Article - 25/01/2010 Prof. Dr. Martin Elmlinger and his colleague Marion Eisenhauer in the laboratory. Elmlinger is holding a ball-pen in his hand, pointing at a microtitre plate Marion Eisenhauer is holding in her hand.<br />

    Intelligent use of suitable biomarkers

    How quickly does a pharmaceutical substance exert its effect? What mechanisms does it use to exert its effect on people and how long does it remain active? In a team headed by Prof. Dr. Martin Elmlinger Nycomed GmbH has developed an efficient biomarker discovery concept specially adapted to the companys requirements and designed to clarify such questions. The concept is specifically geared to the phases and requirements of the companys projects.…

    https://www.gesundheitsindustrie-bw.de/en/article/news/intelligent-use-of-suitable-biomarkers
  • Press release - 17/10/2008

    From protein complex to network

    “In order to fully understand an organism, it is necessary to consider it as a whole,” said Dr. Uwe Schulte, biochemist and CEO of Logopharm GmbH in Freiburg. A growing number of scientists hold the same view, and there is a growing inclination to research the big picture. This is reflected in the continuously increasing number of projects looking into systems biology research.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/from-protein-complex-to-network
  • Vision Zero in oncology - 02/09/2019 Titelcover_Vision-Zero.jpg

    Call for a comprehensive master plan for preventing and treating cancer

    While a cancer-free world may seem unrealistic given the increasing numbers of cancer cases, we need to reach a social consensus that cancer deaths are unacceptable and that everything possible must be done to prevent them. Leading cancer researchers around the world are calling for more investment in prevention research and cancer screening to move towards the vision of a near cancer-free world.

    https://www.gesundheitsindustrie-bw.de/en/article/news/call-for-comprehensive-master-plan-preventing-treating-cancer
  • Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB - 24/04/2020 Das Foto zeigt den Immustick, wobei eine Lösung auf das Auftragsfenster pipettiert wird.

    A rapid pyrogen test: the human immune system as model

    Every year, around 11 million people die of sepsis (blood poisoning) caused by microorganisms or microbial residues, known as pyrogens, entering the bloodstream. The smallest amounts can trigger fever. Researchers from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart have developed a pyrogen test that does not require a laboratory and is not tested on animals. It is expected to be placed on the market soon.

    https://www.gesundheitsindustrie-bw.de/en/article/news/A-rapid-pyrogen-test-the-human-immune-system-as-model
  • Press release - 12/05/2020

    CeGaT Offers Corona Antibody Test

    Since May 11, 2020, CeGaT offers a CE certified corona antibody test. This test determines whether a person has antibodies against the coronavirus SARS-CoV-2. People who have antibodies are assumed to have undergone a coronavirus infection and are highly likely to be immune.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cegat-bietet-corona-antikoerpertest
  • Article - 28/08/2017 Schematic showing the device and the test carrier.

    SpinDiag GmbH – rapid test makes it difficult for pathogens

    Antibiotic-resistant pathogens are becoming an increasing problem, especially in hospitals. Infected patients must be isolated as soon as possible. However, appropriate methods for testing patients upon admission to hospital and isolating them if necessary are still lacking. A young biotechnology company from Baden-Württemberg called SpinDiag GmbH has developed a cost-effective method for the rapid testing of microbial resistance in normal…

    https://www.gesundheitsindustrie-bw.de/en/article/news/spindiag-gmbh-rapid-test-makes-it-difficult-for-pathogens
  • Biosensor - 13/11/2018 Schematic showing the workflow that is required for obtaining a test result with paper strip, pipette, darkness and camera. A test result showing circles with different shades of blue and red.

    Rapid medical test for at-home use

    For quite a number of illnesses, patients need to have the concentrations of the medications they are taking and their blood metabolites checked on a regular basis, which can make life rather difficult. Researchers at the Max Planck Institute for Medical Research in Heidelberg have now developed a test based on the firefly enzyme luciferase. This enzyme can be used to quickly and cheaply measure parameters of interest.

    https://www.gesundheitsindustrie-bw.de/en/article/news/rapid-medical-test-for-at-home-use
  • microRNA as a prognostic biomarker - 13/01/2022 Screen of an ECG device showing the typical action potentials of the heart muscle.

    Heart attack diagnosis: fast and unambiguous thanks to artificial intelligence

    People that arrive in emergency rooms with chest pain require swift action in order to rule out a heart attack or to initiate vital life-saving therapy. However, despite many advances, current tests are not yet optimal: they either take hours or produce false-positive results. Researchers at Heidelberg University Hospital are now using AI in an approach that takes microRNAs from a blood sample to specifically diagnose ‘acute coronary syndrome’.

    https://www.gesundheitsindustrie-bw.de/en/article/news/heart-attack-diagnosis-fast-and-unambiguous-thanks-artificial-intelligence
  • Article - 22/02/2010 10696_de.jpg

    Treasure trove of data from Ulm helps in the understanding of community-acquired pneumonia

    CAP community-acquired pneumonia is a common type of pneumonia that mainly affects young and old people. In Germany around 800000 people contract CAP every year and almost one third has to be admitted to hospital exceeding the number of admissions due to cardiac infarction or stroke. The CAPNETZ competence network which up until recently was funded by the German government is gradually shedding light on a hitherto little known disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/treasure-trove-of-data-from-ulm-helps-in-the-understanding-of-community-acquired-pneumonia
  • Big Data - 13/03/2018 Viegas-User-Activity-on-Wikipedia.png

    “More data does not automatically imply more knowledge“

    In Germany, one of the big names in evidence-based medicine is Prof. Dr. rer. nat. Gerd Antes, co-director of Cochrane Germany. In the following interview, Antes talks about the hype surrounding big data, warns against false promises and reminds us about what is taken for granted.

    https://www.gesundheitsindustrie-bw.de/en/article/news/more-data-does-not-automatically-imply-more-knowledge
  • Press release - 26/03/2010 10875_de.jpg

    Restarting the muscular engine – Research Prize awarded to two medical practitioners from Ulm and Heidelberg

    Dr. Karin Jurkat-Rott, associate professor at the Institute of Applied Physiology at the University of Ulm, and Dr. Marc-André Weber, associate professor and chief physician in the Department of Radiology at the Heidelberg University Hospital, were awarded the Eva Luise Köhler Research Prize for Rare Diseases in Berlin on 1st March 2010. The prize was awarded by Luise Köhler in the presence the German Federal President Horst Köhler, the German…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/restarting-the-muscular-engine-research-prize-awarded-to-two-medical-practitioners-from-ulm-and-heid
  • Article - 30/05/2016 The photo shows a next-generation sequencer consisting of a sequencing unit and a desktop computer.

    The unknown dark spot of the microcosm

    The world of microorganisms is still largely unknown. Researchers such as Kai Sohn from the Fraunhofer IGB in Stuttgart are working on decoding, analysing and gradually gaining a better understanding of the microbial genome. In their search for new enzymes and other biomolecules, both biotechnologists and pharmacologists are interested in micoorganisms, and physicians are hoping that detailed insights into the microbial genome will lead to the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-unknown-dark-spot-of-the-microcosm
  • Press release - 25/09/2020

    Bosch’s new rapid coronavirus test delivers reliable results in 39 minutes

    Bosch has developed a new rapid test for its Vivalytic analysis device to detect the SARS-CoV-2 pathogen. The test provides a reliable result in 39 minutes and is currently the fastest polymerase chain reaction (PCR) test worldwide.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/boschs-new-rapid-coronavirus-test-delivers-reliable-results-39-minutes
  • Assay to support the diagnosis of autoimmune diseases - 22/06/2022 Immunkomplexe_sIC-assay_Teaser.jpg

    Tracking down pathogenic immune complexes

    Soluble complexes of antibodies and their target structures circulating in the blood can trigger serious systemic inflammations. Dr. Philipp Kolb and Haizhang Chen from the Institute of Virology at the Freiburg University Medical Centre have developed a sensitive, cell-based test system for detecting these immune complexes. The system can be used to diagnose systemic autoimmune diseases, and also severe cases of COVID-19.

    https://www.gesundheitsindustrie-bw.de/en/article/news/tracking-down-pathogenic-immune-complexes
  • Company profile - 05/07/2016 Logo_final.jpg

    HS-Analysis GmbH – using digital histology to develop new drugs

    The idea of analysing tissue samples automatically sounds more of a pipe dream than anything else. However, it already happens. HS-Analysis GmbH's ability to interpret tissue samples automatically is driving new drug development a decisive step forward.

    https://www.gesundheitsindustrie-bw.de/en/article/news/hs-analysis-gmbh-using-digital-histology-to-develop-new-drugs
  • Article - 17/10/2011 15525_de.jpg

    “The only way of keeping competition in the international market at bay”

    Biotech companies operate mostly on a global level. This is either because they follow their customers or because their major markets are abroad or because their domestic markets are so small that they are obliged to market their products abroad. Patents do not play a key role in all industries, but are of decisive strategic importance in the biotechnology sector. "However, patents are not always the best," says Ulrike Cremer, a patent…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-only-way-of-keeping-competition-in-the-international-market-at-bay
  • TGU Varimol - 24/07/2020 Das Bild zeigt zwei kleine braune Chemikalienfläschchen, die alle nötigen Reagenzien für ihre Anwendung für Kunden der Varimol enthalten.

    Click chemistry for new medical procedures

    Using a simple molecular click process, biochemists have been able to connect ring-shaped molecules with each other and couple therapeutically active substances to these molecules. Drugs can thus be specifically delivered to diseased cells and used for imaging processes or biosensors. The Stuttgart-based start-up Varimol is using this new technology to provide its customers with tailored applications that are as simple to use as a kit.

    https://www.gesundheitsindustrie-bw.de/en/article/news/click-chemistry-new-medical-procedures
  • Press release - 18/11/2021

    Overcoming resistance to cancer treatment: bone and soft tissue tumors in adolescents as a model system

    Treatment resistance is a central problem in the treatment of cancer. Bone and soft tissue tumors – known as sarcomas – in adolescents and young adults often stop responding to treatment too. This is because cancer cells develop a large number of new characteristics as the disease progresses and often become resistant to drugs that were originally effective.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-resistance-cancer-treatment-bone-and-soft-tissue-tumors-adolescents-model-system
  • Neurodegenerative diseases - 12/12/2022 Darstellung mehrerer Neuronen mit langen Zellfortsätzen, zwischen denen sich kugelförmige Beta-Amyloid-Aggregate befinden. Die  Zellkörper sind von pTau-Fibrillen durchzogen.

    Blood-based biomarkers allow the early prediction of Alzheimer's risks

    Most dementia diseases develop insidiously and are only detected at an advanced stage. Researchers at the University of Heidelberg and the German Cancer Research Center (DKFZ) have now identified the glial fibre acidic protein (GFAP) in the blood as a promising biomarker that can be used to determine an increased risk of developing Alzheimer's disease up to 17 years before diagnosis.

    https://www.gesundheitsindustrie-bw.de/en/article/news/blood-based-biomarkers-allow-early-prediction-alzheimers-risks
  • Article - 04/07/2016 The schematic shows how oesophageal cells develop into the two major types of oesophageal cancer.

    Epigenetic modifications for the treatment of oesophageal cancer

    Oesophageal cancer is a rare but highly aggressive type of cancer with a rather poor prognosis. Dr. Theresa Ahrens, a researcher in a group led by Prof. Dr. Silke Laßmann and Prof. Dr. Martin Werner at the Institute of Clinical Pathology at the Freiburg University Medical Centre, has tested a variety of epigenetic drugs that can interfere with the development of oesophageal cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/modifikation-epigenetic-modifications-for-the-treatment-of-oesophageal-cancer-als-therapie-bei-speiseroehrenkrebs

Page 16 / 17

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search